Research from the American Diabetes Association shows that GLP-1 medications can increase the risk of muscle loss, and patients are often advised to consume more protein to preserve muscle
The presence of non-responders to GLP-1R therapy continues to complicate treatment outcomes, underscoring the need for a deeper understanding of individual variability in response [117,118]
April 2, 2025: Lawsuits Against Eli Lillys Trulicity Increase in March There are now 1,685 active lawsuits pending against Trulicitys maker Novo Nordisk and other GLP-1 manufacturers
Who Should Consider GLP-1 Therapy and the Role of Genetic Context GLP-1 therapy applies to adults with BMI 30 kg/m or 27 with weight-related conditions, or those with type 2 diabetes
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression
Phentermine 15mg outcomes in early non-responders A pivotal double-anonymized, randomized controlled proof-of-principle study evaluated whether augmenting BT with AOM improved weight loss outcomes compared to BT with placebo in early non-responders
